Grail's Multi-Cancer Blood Test Gets FDA Committee Vote for Premarket Approval
By Katherine HamiltonGrail Inc. received a favorable vote from a Food and Drug Administration panel regarding premarket approval for its Galleri multi-cancer early detection test.The cancer-detection company said the FDA's medical devices advisory committee voted 7-2, with one abstention, to greenl…